Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 12:54 PM
Ignite Modification Date:
2025-12-24 @ 12:54 PM
NCT ID:
NCT05821361
Brief Summary:
To evaluate the efficacy and safety of HAIC combined with Cadonilimab and bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma
Detailed Description:
An open label, single-arm, single center, phase II study evaluating HAIC combined with cadonilimab and bevacizumab as first-line therapy in unresectable hepatocellular carcinoma
Study:
NCT05821361
Study Brief:
Protocol Section:
NCT05821361